

October 2024

one
nucleus™

ON eNews



Welcome to this month's eNews



Reasons to be Optimistic?

As anticipated in my eNews welcome last month, the more upbeat feeling of investment trends, dealmaking, innovative programmes, and approvals continues to play out. More biotech IPO activity is being observed. Last month saw five successful IPOs, a marked upturn compared to late, [as reported by Xtalks](#) and others.

Exciting new partnerships announced have included [Tesselate BIO](#) with Omico and CMRI; [LinkGeivity](#) receiving its Deep-Tech EU grant to support its sought after founding round; and [Owlstone Medical](#) entering into a long-term collaboration with the FDA. Approval of a new type of schizophrenia drug for the first time in decades from [Bristol Myers Squibb](#) by the FDA demonstrates how advances are being made in the most complex areas of unmet need.

Engaging Our Members and Their Peers



Whilst the One Nucleus team has delivered, with sponsors and partners, a variety of events locally that have included the Autumn Life Sciences Dinner, Innovation Seminars, BioWednesdays, Training Courses and Special Interest Groups, it has also been excellent to lead another mission to Boston for their Biotech Week.

Supported by [BABCNE](#), the [UK Department of Business & Trade \(New England\)](#) and a host of MA-based connections, the highlight was the UK Pitching Day, hosted at Wolf Greenfield in the impressive Federal Reserve Building, followed by a Boston Bio Brits networking reception. A huge thank you to the UK companies for travelling to pitch which included: [Microbiotica](#), [Cumulus Oncology](#), [AisleVax](#), [Outsee](#), [Oncimmune](#), [ExpressionEdits](#), [Carocell Bio](#), [Drishti Discoveries](#), and [PrecisionLife](#).

Are You in the Know?

To stay informed of all One Nucleus updates, disseminate your company's news, or track the announcements from other members, you can make full use of our [website](#), [LinkedIn](#), or [X](#) pages. The [news stream](#) contains numerous updates from our community. Enjoy the read (and check out the new [One Nucleus website](#))!

Tony Jones, CEO, One Nucleus

Genesis 2024

Maximising Returns from Life Science
Innovation

📍 1 Wimpole Street, London

📅 4 December 2024

one
nucleus™

.....

Navigate Your Opportunities with Ease - Introducing the New Look One Nucleus Website

A challenge for busy life science professionals seeking to build collaboration with the right contacts in a sea of potential opportunities, is navigating these waters quickly and saving crucial time and effort. To help you find the right opportunities, One Nucleus has unveiled a new and improved One Nucleus website. [Read the article here.](#)

How Can You Stay One Step Ahead in the Ever More Competitive Drug Discovery Space?

In answer to macro challenges faced by life science companies, Domainex launches a new webinar series, hosted by One Nucleus, to discuss the latest approaches and technologies that will be vital in any drug discovery programme. [Read more here.](#)

What Makes Transfer Pricing an Important Issue for Growing Life Sciences Businesses?

Life sciences businesses often expand internationally while they are still at a relatively early point in their lifecycle and getting that expansion right is especially fundamental to their long-term commercial success. International consulting services company RSM outlines how transfer pricing comes into this. [Read more here.](#)

Celebrating Success: Putting Your Business in the Spotlight

The One Nucleus Annual Awards seek to recognise excellence across the whole Life Science ecosystem given the vital role each stakeholder plays; find out how you can participate [here.](#)

Are You a Bio-Innovation Trend Setter? Join the ON Helix Review

If you find the [ON Helix conference](#) a valuable forum for addressing key bio innovation trends, you may be interested in putting your organisation in front of other like-minded professionals. The ON Helix Review, launching at BIO-Europe is in the final stages of production, and you can include an advert in the 2024 issue. But time is ticking! If you would like to advertise, from £500+VAT, please email natalie@onenucleus.com **by Friday 4 October.**

Equity Investment Into Spinouts 2024

Academic spinouts play a crucial role in transforming cutting-edge research and intellectual property from UK universities into innovative commercial ventures. Which are the top performing UK universities? [Read more here](#) from Beauhurst and Parkwalk Advisors.

Aiming for 'Magic Bullets' in Medicine: Are We Shooting Ourselves in the Foot?


[A short but thought-provoking read](#) by Eleanor Ward, Clarivate, challenging whether the pursuit of that cure-all medicine could potentially hinder the assessment of other innovative medicines.

Celebrate the Groundbreaking of Vitrum by Breakthrough - The Newest Destination for R&D in the Cambridge UK Ecosystem

Attention biotech, pharma and investors! Limited places are remaining to join

prominent leaders and stakeholders in the life science industry for an exclusive event at the AstraZeneca Discovery Centre (DISC) in Cambridge to celebrate the groundbreaking of a cutting-edge life science facility. [RSVP here](#) - places will be confirmed after registration of interest.

December 4 Genesis & RESI – Your Route Evolves



Returning to the matters at home, excitement is building as we move to just nine weeks to what many might call the highlight of the year in London - [Genesis](#). The keynote programme, sponsor and exhibitor line-ups and networking opportunities are shaping up to deliver another memorable connecting and knowledge-sharing event.

Feedback in previous years has often included the question of why there are no company pitching sessions at Genesis.

The answer has been easy; we wanted to retain the clarity of the Genesis mission unless we could bring something truly additive to the UK calendar, rather than just noise. Feedback, complemented by my attendance at their equivalent event in Boston recently, has convinced me that we have now found that truly additive evolution – [RESI London](#). Having RESI take place immediately next door to Genesis adds a unique environment for those companies developing devices, diagnostics, digital, or drug products wanting to pitch to and meet global investors matched to their particular needs and focus. As a strategic partnership, attendees can choose to:

- Attend Genesis only
- Attend RESI London only
- Receive a reciprocal discount to attend both – building their own agenda for the day to come and go and maximise their engagement.



Expanding to the US? Danforth Advisors

We help UK biotech companies launch stateside and scale with efficiency.

Banking and accounting | HR compliance | Payroll and benefits | Financing strategy
Investor relations | Insurance assessment | Clinical operations





One Nucleus Events

Training Courses

Industry News

Corporate Patron



Corporate Sponsors



Copyright © 2024

One Nucleus is an international membership organisation for life science and healthcare companies.